1-7 of 7
Brian Elliott
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1-3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)

Jeff P. Sharman, Ralph V. Boccia, Thomas Doerr, Kristin Conte, Yang Bai, Brian Elliott, David J. Andorsky
Journal: Blood
Blood (2022) 140 (Supplement 1): 9491–9492.
https://doi.org/10.1182/blood-2022-157575
Published: 2022
Journal Articles

Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

Andrew Ip, Alex Mutebi, Tongsheng Wang, Monika P. Jun, Anupama Kalsekar, Fernando Rivas Navarro, Anthony Wang, Rajesh Kamalakar, Mariana Sacchi, Brian Elliott
Journal: Blood
Blood (2022) 140 (Supplement 1): 6693–6694.
https://doi.org/10.1182/blood-2022-159569
Published: 2022
Journal Articles

Phase 1b Trial of Subcutaneous Epcoritamab in Pediatric Patients with Relapsed or Refractory (R/R) Aggressive Mature B-Cell Neoplasms (EPCORE Peds-1)

Mitchell S. Cairo, Mark A. Rocco, John Bernard, Satya R. Siddani, Apurvasena Parikh, Brian Elliott, Birgit Burkhardt
Journal: Blood
Blood (2022) 140 (Supplement 1): 3827–3828.
https://doi.org/10.1182/blood-2022-157546
Published: 2022
Journal Articles

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, MD PhD, Peter Johnson, MD FRCP, Kim M Linton, MBChB, PhD, Martine E.D. Chamuleau, MD PhD, David John Lewis, MD, Anna Sureda Balari, MD PhD, David Cunningham, MD FRCP, FMedSci, Roberto S Oliveri, MD PhD, Dena DeMarco, Brian Elliott, MD, Kuo-mei Chen, PhD, Pieternella J. Lugtenburg, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-133820
Published: 2020
Journal Articles

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Julie Kanter, MD, Darla K Liles, MD, Kim Smith-Whitley, MD, Clark Brown, MD PhD, Abdullah Kutlar, MD, Brian Elliott, Amit Shah, Jeremie Lincy, Susan Poggio, Kenneth I. Ataga, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 991.
https://doi.org/10.1182/blood-2019-123965
Published: 2019
Journal Articles

Rationale and Design of a Phase II Open-Label, Multicenter Study to Assess the Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Adult Patients with Sickle Cell Disease

Julie Kanter, MD, Brian Elliott, Denis Weber, Chiaki Tanaka, Fang Xiang, Kenneth I Ataga, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4782.
https://doi.org/10.1182/blood.V130.Suppl_1.4782.4782
Published: 2017
Journal Articles

Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia

Gabriel Tremblay, DBA, MSc, BS, Menaka Bhor, PhD, Anuja Roy, PhD, Brian Elliott, MD, Mike Dolph, MSc BHSc, Anna Forsythe, PharmD, MSc, MBA, Andrew Briggs, DPhil
Journal: Blood
Blood (2017) 130 (Supplement 1): 2146.
https://doi.org/10.1182/blood.V130.Suppl_1.2146.2146
Published: 2017